fMRI study with OROS-methylphenidate treatment in pediatric ADHD

fMRI study with OROS-methylphenidate treatment in pediatric ADHD - fMRI study in ADHD with OROS-methylphenidate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008460

Enrollment

Registered

2012-08-08

Start date

2010-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD

Interventions

Patient group 3 months 1mg/kg daily Control group No treatment

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Children and adolescents with ADHD who met the Diagnostic and Statistical Manual of Mental Disorders DSM-IV Text Revision (DSM-IV-TR) criteria. Healthy children and adolescents with higher level of IQ 80.

Exclusion criteria

Exclusion criteria: Participants were excluded who had any history of substance abuse, recent substance use, head trauma with loss of consciousness, epilepsy, significant fetal exposure to alcohol or drugs, perinatal or neonatal complications, neurological disorders, or medical conditions that could adversely affect growth and development.

Design outcomes

Primary

Measure	Time frame
Brain function before and after a 3-month treatment with osmotic release oral system-methylphenidate	—

Secondary

Measure	Time frame
ADHD-RS score	—

Countries

Japan

Contacts

Public ContactAkemi Tomoda

University of Fukui Research Center for Child Mental Development, Graduate School of Medical Sciences

atomoda@u-fukui.ac.jp0776-61-8691

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026